Nephrocare Health Services Ltd (NEPHROPLUS) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company reported strong performance in Q3 FY26, driven by a 32% year-on-year revenue growth, attributed to favorable factors like a price increase and acquisitions in the Philippines, along with a CGHS price hike in India.
- International operations have significantly scaled, with their revenue contribution increasing from 12% in FY23 to 41% in the nine months of FY26, underscoring the successful leverage of the India-based platform in higher-priced geographies.
- The company demonstrated robust profitability improvement, with adjusted EBITDA growing 43.1% YoY to Rs. 63 crores and adjusted PAT increasing by 71% YoY in Q3, reflecting strong operating leverage as the business scales.
- Management has established a clear long-term growth strategy focused on three drivers: ramping up existing clinics, rolling up new clinics in current markets, and strategic forays into new countries or large-scale PPP projects.
- The company maintains a strong financial position with a negative net debt of Rs. 283.6 crores and a healthy operating cash flow to EBITDA conversion of 65%, positioning it well to fund future organic and inorganic expansion.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.